Stratégies de traitement global du cancer de la prostate – du stade localisé à haut risque au CPRC
Organisateur :
healthbook.org
Date :
December 10, 2025
Durée :
17:30 – 19:00 Uhr (90 min)
Public cible :
Oncologues médicaux, radio-oncologues, spécialistes en médecine nucléaire et urologues de Suisse, d’Allemagne et d’Autriche (région DACH)
Langue :
Français
Chair :
PD Dr Alex Friedlaender (Oncologie); Clinique Générale-Beaulieu, Genève
Expert Panel: 1 expert par spécialité:
Radio-oncologie:
Dr Vérane Achard, HUG & Bergonié Institute Bordeaux
Médecine nucléaire :
Dr Nicola Bianchetto Wolf, HUG Geneva
Urologie :
Dr Gregory Wirth, Clinique Générale-Beaulieu, Genève
Oncologie:
Dr Marie-Laure Amram, Clinique et Permanence d’Onex
Objective :
As part of this CME-accredited healthbook Live Tumor Board, the focus is on interdisciplinary exchange—with particular attention to the latest insights into innovative treatment strategies for prostate cancer (e.g. ESMO data).
The goal is to provide a comprehensive understanding of the entire disease spectrum—from localized high-risk stages to castration-resistant prostate cancer (CRPC).
Using four real-world patient cases—one with localized high-risk prostate cancer, two with metastatic hormone-sensitive prostate cancer (mHSPC), and one with metastatic CRPC (mCRPC)—diagnostic and therapeutic decisions across various stages of disease progression will be discussed live.
This format supports participating physicians in developing evidence-based and personalized treatment concepts—aimed at improving the quality of care in the long term and delivering practical, actionable insights for clinical routine.